Vertex Pharmaceuticals (VRTX) Depreciation & Amortization (CF) (2009 - 2026)

Vertex Pharmaceuticals' Depreciation & Amortization (CF) history runs 18 years deep, the most recent figure standing at $55.9 million for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 15.5% year-over-year to $55.9 million in Q1 2026; TTM through Mar 2026 was $217.3 million, a 7.52% increase from a year earlier, with the FY2025 full-year figure at $209.8 million, up 1.25% from the prior year.
• Depreciation & Amortization (CF) held at $55.9 million in Q1 2026 per VRTX's latest filing, from $55.7 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $59.0 million in Q4 2023 and bottomed at $35.9 million in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $48.4 million (2025), against an average of $47.2 million.
• Across the five-year window, Depreciation & Amortization (CF) surged 53.65% in 2023 and slipped 21.19% in 2024, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $38.4 million in 2022, then jumped by 53.65% to $59.0 million in 2023, then declined by 21.19% to $46.5 million in 2024, then rose by 19.78% to $55.7 million in 2025, then advanced by 0.36% to $55.9 million in 2026.
• Per Business Quant, the three latest VRTX Depreciation & Amortization (CF) figures stand at $55.9 million (Q1 2026), $55.7 million (Q4 2025), and $54.0 million (Q3 2025).